{"id":2205,"date":"2026-10-04T18:45:49","date_gmt":"2026-10-04T22:45:49","guid":{"rendered":"https:\/\/simplelifescience.com\/can-small-molecule-synthesis-be-combined-with-peptide-synthesis\/"},"modified":"2026-10-04T18:45:49","modified_gmt":"2026-10-04T22:45:49","slug":"can-small-molecule-synthesis-be-combined-with-peptide-synthesis","status":"publish","type":"post","link":"https:\/\/simplelifescience.com\/es\/can-small-molecule-synthesis-be-combined-with-peptide-synthesis\/","title":{"rendered":"Can small molecule synthesis be combined with peptide synthesis?"},"content":{"rendered":"<style>.pseo-content { font-size: 17px; line-height: 1.7; color: inherit; }\n.pseo-content h2 { font-size: 1.6em; margin-top: 1.8em; margin-bottom: 0.6em; line-height: 1.3; color: inherit; }\n.pseo-content h3 { font-size: 1.25em; margin-top: 1.5em; margin-bottom: 0.4em; line-height: 1.35; color: inherit; }\n.pseo-content h4 { color: inherit; }\n.pseo-content p { margin: 0 0 1em; }\n.pseo-content ul, .pseo-content ol { margin: 0 0 1em 1.4em; padding: 0; }\n.pseo-content li { margin: 0.3em 0; }\n.pseo-content strong { font-weight: 600; }\n.pseo-content blockquote { margin: 1.2em 0; padding: 0.6em 1em; border-left: 3px solid color-mix(in srgb, currentColor 30%, transparent); background: color-mix(in srgb, currentColor 4%, transparent); color: inherit; }\n.pseo-content a { text-decoration: underline; }<\/p>\n<p>.pseo-content .pseo-table-wrap { overflow-x: auto; margin: 1.4em 0; -webkit-overflow-scrolling: touch; }\n.pseo-content table { width: 100% !important; border-collapse: collapse !important; table-layout: auto !important; font-size: 0.96em; }\n.pseo-content table th,\n.pseo-content table td {\n  padding: 10px 12px !important;\n  border-bottom: 1px solid color-mix(in srgb, currentColor 14%, transparent) !important;\n  border-left: none !important;\n  border-right: none !important;\n  vertical-align: top !important;\n  text-align: left !important;\n  word-break: break-word !important;\n  overflow-wrap: anywhere !important;\n  white-space: normal !important;\n}\n.pseo-content table th {\n  background: color-mix(in srgb, currentColor 6%, transparent) !important;\n  color: inherit !important;\n  font-weight: 600 !important;\n  border-top: 1px solid color-mix(in srgb, currentColor 14%, transparent) !important;\n}\n.pseo-content table tr:last-child td { border-bottom: 1px solid color-mix(in srgb, currentColor 14%, transparent) !important; }<\/style>\n<div class=\"pseo-content\">\n<p>Yes, small molecule synthesis and peptide synthesis can be combined in a single research program, and the combination is standard practice for producing peptide-drug conjugates, lipidated peptides, and stapled or PROTAC-like constructs. The peptide backbone is typically assembled first via solid-phase peptide synthesis (SPPS), then a small molecule payload, linker, or fatty acid chain is attached through solution-phase chemistry either on-resin or after cleavage. The catch most researchers miss: combining the two disciplines multiplies the analytical burden, because each conjugation step needs its own purity check before the next stage can start.<\/p>\n<div class=\"pseo-tldr\" style=\"display:flow-root;clear:both;margin:32px 0;padding:24px 28px;border:1px solid;border-color:rgba(128,128,128,0.35);border-color:color-mix(in srgb, currentColor 14%, transparent);border-left:3px solid;border-left-color:rgba(128,128,128,0.6);border-left-color:color-mix(in srgb, currentColor 30%, transparent);border-radius:12px;background-color:rgba(128,128,128,0.06);background-color:color-mix(in srgb, currentColor 4%, transparent);max-width:100%;\">\n<div class=\"pseo-tldr-label\" style=\"font-size:11px;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:rgba(128,128,128,0.9);color:color-mix(in srgb, currentColor 55%, transparent);margin-bottom:12px;\">TL;DR<\/div>\n<ul style=\"float:none;margin:0;padding-left:20px;list-style:disc;\">\n<li style=\"float:none;margin:8px 0;font-size:15px;line-height:1.6;color:inherit;\">Small molecule synthesis can be combined with peptide synthesis for conjugates, lipidated peptides, and stapled peptide constructs.<\/li>\n<li style=\"float:none;margin:8px 0;font-size:15px;line-height:1.6;color:inherit;\">SPPS builds the peptide backbone first; small-molecule attachment happens on-resin or in solution-phase afterward.<\/li>\n<li style=\"float:none;margin:8px 0;font-size:15px;line-height:1.6;color:inherit;\">Each conjugation step requires its own analytical checkpoint, not just a final purity check on the finished molecule.<\/li>\n<li style=\"float:none;margin:8px 0;font-size:15px;line-height:1.6;color:inherit;\">Simple Life Science runs combined peptide\/small-molecule synthesis as a defined, staged process with lot documentation at each step.<\/li>\n<\/ul>\n<\/div>\n<h2>Why this matters<\/h2>\n<p>Most research peptide catalogs list unmodified sequences: linear chains, cyclic variants, maybe a fluorescent tag. But a growing share of active research projects \u2014 GLP-1 receptor agonist analogs, antibody-peptide conjugates, cell-penetrating peptide carriers for small-molecule payloads \u2014 require a hybrid molecule that no off-the-shelf catalog covers. Getting that hybrid built correctly depends on whether a synthesis provider treats it as two separate jobs stitched together, or as a single defined process with its own specification from the start. That distinction determines whether the final lot actually matches what was ordered.<\/p>\n<h2>Can small molecule synthesis be combined with peptide synthesis?<\/h2>\n<p>The combination happens through a defined sequence of stages rather than a single unified reaction. Here&#39;s how the process typically runs:<\/p>\n<ol>\n<li><strong>Define<\/strong> \u2014 the target molecule&#39;s structure is specified: peptide sequence, small-molecule component (linker, payload, or fatty acid), and the exact attachment point (side chain, N-terminus, C-terminus).<\/li>\n<li><strong>Plan<\/strong> \u2014 the synthetic route is mapped, including which protecting groups stay orthogonal so the small-molecule coupling step doesn&#39;t disturb the peptide backbone.<\/li>\n<li><strong>Produce<\/strong> \u2014 the peptide is assembled via SPPS, then the small-molecule component is coupled either on-resin (before cleavage) or in solution-phase (after cleavage and purification of the peptide intermediate).<\/li>\n<li><strong>Verify<\/strong> \u2014 analytical review at each checkpoint: LC-MS confirms mass and identity, HPLC confirms purity, before the molecule advances to the next stage.<\/li>\n<li><strong>Document<\/strong> \u2014 lot documentation captures each intermediate&#39;s analytical data, not just the final conjugate&#39;s certificate of analysis.<\/li>\n<\/ol>\n<p>| Approach | What gets combined | Typical use case | Analytical complexity |<br \/>\n|&#8212;|&#8212;|&#8212;|<br \/>\n| On-resin conjugation | Small molecule attached before peptide cleavage | Lipidated peptides, some linker chemistries | Moderate \u2014 fewer purification cycles |<br \/>\n| Solution-phase coupling | Small molecule attached after peptide is purified | Peptide-drug conjugates, PROTAC-like constructs | Higher \u2014 separate purification per intermediate |<br \/>\n| Convergent synthesis | Peptide and small-molecule fragments built separately, joined last | Complex hybrids with sensitive functional groups | Highest \u2014 requires independent QC on both fragments |<\/p>\n<p><strong>Convergent synthesis wins on control when the small-molecule fragment is chemically sensitive; on-resin conjugation wins on speed when the attachment chemistry is well-established.<\/strong><\/p>\n<h3>Peptide-drug conjugates: linking a peptide carrier to a small-molecule payload<\/h3>\n<p>A peptide-drug conjugate uses a peptide sequence \u2014 often one selected for a targeting or cell-penetrating property \u2014 as a carrier for a small-molecule payload joined through a cleavable or stable linker. The peptide and the payload are usually synthesized as separate defined components, then joined at a specified stage with its own analytical checkpoint. <strong>Best for<\/strong> researchers studying targeted delivery mechanisms rather than the peptide sequence alone.<\/p>\n<h3>Lipidated peptides: attaching a fatty acid chain to a peptide backbone<\/h3>\n<p>Acylation with a fatty acid or fatty diacid chain \u2014 the chemistry behind long-acting GLP-1 receptor agonist analogs \u2014 is one of the most common small-molecule-to-peptide combinations in current research. The fatty acid is typically attached on-resin at a specific lysine side chain before cleavage. <strong>Best for<\/strong> half-life and albumin-binding research where the modification site is already defined in the literature.<\/p>\n<h3>Stapled peptides: small-molecule crosslinkers locking secondary structure<\/h3>\n<p>A small-molecule crosslinker \u2014 often a hydrocarbon staple installed via ring-closing metathesis \u2014 locks a peptide into a helical conformation it wouldn&#39;t hold unmodified. This requires non-natural amino acids at defined positions and a distinct small-molecule coupling step separate from standard SPPS. <strong>Best for<\/strong> structural biology research on protein-protein interaction targets, not for routine peptide production.<\/p>\n<h3>PROTAC-like constructs: a peptide fragment linked to a small-molecule warhead<\/h3>\n<p>Some degrader-style research constructs combine a peptide-recognition element with a small-molecule warhead joined by a synthetic linker. Both fragments are synthesized independently, characterized, and then coupled in a final convergent step. <strong>Best for<\/strong> early-stage degrader research where the peptide component substitutes for a small-molecule binder that hasn&#39;t been identified yet.<\/p>\n<h2>Why the process varies from project to project<\/h2>\n<ul>\n<li><strong>Attachment chemistry<\/strong> \u2014 an amide coupling behaves differently than a click chemistry reaction or a metathesis-based staple, and each dictates which protecting groups can survive the sequence.<\/li>\n<li><strong>Order of operations<\/strong> \u2014 on-resin attachment before cleavage versus solution-phase coupling after purification changes how many discrete intermediates need independent analytical review.<\/li>\n<li><strong>Solubility of the small-molecule component<\/strong> \u2014 fatty acid chains and hydrophobic linkers often force a switch from standard aqueous purification to organic-phase HPLC methods.<\/li>\n<li><strong>Scale<\/strong> \u2014 a milligram-scale research batch tolerates more manual intervention than a bulk peptide API run intended for downstream formulation work.<\/li>\n<li><strong>Stability of the conjugate<\/strong> \u2014 some linker chemistries degrade under standard lyophilization conditions, which changes how the final lot is dried and stored.<\/li>\n<li><strong>Analytical requirements<\/strong> \u2014 a conjugate with a UV-silent small-molecule component may need mass spec confirmation at every stage instead of relying on HPLC peak area alone.<\/li>\n<\/ul>\n<p>Simple Life Science structures combined peptide and <a href=\"https:\/\/simplelifescience.com\/\">small-molecule synthesis projects<\/a> as a staged specification rather than a single black-box reaction, so each intermediate carries its own analytical record before the next coupling step proceeds.<\/p>\n<h2>Does bulk peptide API production support small-molecule conjugation at scale?<\/h2>\n<p>Bulk peptide API runs can support a downstream conjugation step, but the decision to scale up combined synthesis depends on whether the attachment chemistry has already been validated at research scale. Reviewing <a href=\"https:\/\/blog.simplelifescience.com\/is-bulk-peptide-api-worth-it-for-a-small-research-lab-in\">whether bulk peptide API makes sense for a small lab<\/a> first helps determine if a conjugation project even needs bulk quantities before the small-molecule component is finalized.<\/p>\n<h3>How often should a combined peptide-small molecule batch be retested for purity?<\/h3>\n<p>A combined batch should be retested at each synthetic stage, not just once at final release, because a conjugation step can introduce new impurities that a single end-point test won&#39;t catch. The guidance on <a href=\"https:\/\/blog.simplelifescience.com\/how-often-should-peptide-batches-be-retested-for-purity\">how often peptide batches should be retested for purity<\/a> applies at every intermediate stage of a hybrid synthesis, not only the finished conjugate.<\/p>\n<h3>Is custom synthesis available for a hybrid peptide-small molecule project?<\/h3>\n<p>Custom synthesis is the standard route for hybrid projects since catalog peptides don&#39;t cover the specific linker or small-molecule attachment a given project requires. A defined specification \u2014 sequence, attachment point, linker chemistry, target purity \u2014 is the starting document for any custom hybrid synthesis quote.<\/p>\n<div class=\"pseo-cta\" style=\"display:flow-root;clear:both;margin:32px 0;padding:28px;border:1px solid;border-color:rgba(128,128,128,0.35);border-color:color-mix(in srgb, currentColor 14%, transparent);border-radius:12px;background-color:rgba(128,128,128,0.06);background-color:color-mix(in srgb, currentColor 4%, transparent);max-width:100%;text-align:center;\">\n<p style=\"margin:0;font-size:20px;font-weight:700;line-height:1.35;letter-spacing:-0.01em;color:inherit;\">Scope a custom hybrid synthesis project<\/p>\n<p style=\"margin:8px 0 0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">Define the peptide and small-molecule specification before quoting a combined synthesis run.<\/p>\n<div style=\"display:flex;flex-wrap:wrap;justify-content:center;gap:10px;margin-top:18px;\"><a class=\"pseo-cta-button\" href=\"https:\/\/simplelifescience.com\/\" style=\"display:inline-block;padding:14px 28px;border:1px solid;border-color:rgba(128,128,128,0.9);border-color:color-mix(in srgb, currentColor 55%, transparent);border-radius:10px;background-color:rgba(128,128,128,0.12);background-color:color-mix(in srgb, currentColor 10%, transparent);font-size:16px;font-weight:700;line-height:1.4;color:inherit;text-decoration:none;\">Start a project<\/a><\/div>\n<\/div>\n<h2>FAQ<\/h2>\n<div class=\"pseo-faq\" style=\"display:flow-root;clear:both;margin:32px 0;padding:8px 28px;border:1px solid;border-color:rgba(128,128,128,0.35);border-color:color-mix(in srgb, currentColor 14%, transparent);border-radius:12px;background-color:rgba(128,128,128,0.06);background-color:color-mix(in srgb, currentColor 4%, transparent);max-width:100%;\">\n<div class=\"pseo-faq-item\" style=\"padding:16px 0;\">\n<p style=\"margin:0 0 6px;font-size:16px;font-weight:700;color:inherit;\">Can small molecule synthesis be combined with peptide synthesis?<\/p>\n<p style=\"margin:0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">Yes, combining them is standard for peptide-drug conjugates, lipidated peptides, and stapled peptide constructs in 2026. The peptide backbone is typically built via SPPS first, then the small-molecule component is attached on-resin or in solution-phase.<\/p>\n<\/div>\n<div class=\"pseo-faq-item\" style=\"padding:16px 0;border-top:1px solid;border-top-color:rgba(128,128,128,0.35);border-top-color:color-mix(in srgb, currentColor 14%, transparent);\">\n<p style=\"margin:0 0 6px;font-size:16px;font-weight:700;color:inherit;\">What is a peptide-drug conjugate?<\/p>\n<p style=\"margin:0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">A peptide-drug conjugate joins a peptide carrier sequence to a small-molecule payload through a defined linker. The peptide and payload are usually synthesized as separate components before being coupled at a specified stage.<\/p>\n<\/div>\n<div class=\"pseo-faq-item\" style=\"padding:16px 0;border-top:1px solid;border-top-color:rgba(128,128,128,0.35);border-top-color:color-mix(in srgb, currentColor 14%, transparent);\">\n<p style=\"margin:0 0 6px;font-size:16px;font-weight:700;color:inherit;\">Do lipidated peptides count as combined synthesis?<\/p>\n<p style=\"margin:0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">Yes, lipidated peptides combine a fatty acid or fatty diacid chain with a peptide backbone, usually attached on-resin at a specific lysine side chain. This is one of the most common hybrid synthesis requests in current peptide research.<\/p>\n<\/div>\n<div class=\"pseo-faq-item\" style=\"padding:16px 0;border-top:1px solid;border-top-color:rgba(128,128,128,0.35);border-top-color:color-mix(in srgb, currentColor 14%, transparent);\">\n<p style=\"margin:0 0 6px;font-size:16px;font-weight:700;color:inherit;\">Does a stapled peptide require small-molecule chemistry?<\/p>\n<p style=\"margin:0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">Yes, a stapled peptide uses a small-molecule crosslinker, often installed via ring-closing metathesis, to lock the peptide into a fixed secondary structure. This requires non-natural amino acids at defined positions.<\/p>\n<\/div>\n<div class=\"pseo-faq-item\" style=\"padding:16px 0;border-top:1px solid;border-top-color:rgba(128,128,128,0.35);border-top-color:color-mix(in srgb, currentColor 14%, transparent);\">\n<p style=\"margin:0 0 6px;font-size:16px;font-weight:700;color:inherit;\">Can bulk peptide API be used as the starting material for a conjugation project?<\/p>\n<p style=\"margin:0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">Bulk peptide API can serve as the peptide component for a downstream conjugation step once the attachment chemistry is validated at research scale. Scaling up before validation risks carrying an unoptimized coupling reaction into a larger batch.<\/p>\n<\/div>\n<div class=\"pseo-faq-item\" style=\"padding:16px 0;border-top:1px solid;border-top-color:rgba(128,128,128,0.35);border-top-color:color-mix(in srgb, currentColor 14%, transparent);\">\n<p style=\"margin:0 0 6px;font-size:16px;font-weight:700;color:inherit;\">How is purity verified on a combined peptide-small molecule batch?<\/p>\n<p style=\"margin:0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">Purity is verified at each synthetic stage using HPLC and LC-MS, not only at final release. A conjugation step can introduce new impurities that a single end-point purity check would miss.<\/p>\n<\/div>\n<div class=\"pseo-faq-item\" style=\"padding:16px 0;border-top:1px solid;border-top-color:rgba(128,128,128,0.35);border-top-color:color-mix(in srgb, currentColor 14%, transparent);\">\n<p style=\"margin:0 0 6px;font-size:16px;font-weight:700;color:inherit;\">Is custom synthesis required for hybrid peptide-small molecule projects?<\/p>\n<p style=\"margin:0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">Custom synthesis is the standard route because catalog peptides rarely include the specific linker or small-molecule attachment a hybrid project needs. The project starts from a defined specification covering sequence, attachment point, and linker chemistry.<\/p>\n<\/div>\n<div class=\"pseo-faq-item\" style=\"padding:16px 0;border-top:1px solid;border-top-color:rgba(128,128,128,0.35);border-top-color:color-mix(in srgb, currentColor 14%, transparent);\">\n<p style=\"margin:0 0 6px;font-size:16px;font-weight:700;color:inherit;\">What documentation should accompany a hybrid synthesis lot?<\/p>\n<p style=\"margin:0;font-size:15px;line-height:1.6;color:rgba(128,128,128,0.95);color:color-mix(in srgb, currentColor 78%, transparent);\">Lot documentation should include analytical data for each intermediate stage, not just a certificate of analysis for the finished conjugate. This lets a researcher trace which stage introduced any deviation from specification.<\/p>\n<\/div>\n<\/div>\n<h2>One last thing<\/h2>\n<p>The fatty acid acylation chemistry behind long-acting GLP-1 receptor agonist analogs is itself a peptide-small molecule hybrid \u2014 the modification that gives these molecules extended half-life is a small-molecule attachment, not a change to the peptide sequence. Most researchers evaluating a combined synthesis project focus on the peptide backbone and treat the small-molecule component as an afterthought, when in 2026 research programs it&#39;s often the attachment chemistry, not the sequence, that determines whether the project succeeds.<\/p>\n<h2>Related guides<\/h2>\n<ul>\n<li><a href=\"https:\/\/blog.simplelifescience.com\/best-lyophilized-peptides-for-research-labs-in\">Best lyophilized peptides for research labs<\/a><\/li>\n<li><a href=\"https:\/\/blog.simplelifescience.com\/best-7-research-peptide-suppliers-in\">Best 7 research peptide suppliers<\/a><\/li>\n<\/ul>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Can small molecule synthesis be combined with peptide synthesis?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes, combining them is standard for peptide-drug conjugates, lipidated peptides, and stapled peptide constructs in 2026. The peptide backbone is typically built via SPPS first, then the small-molecule component is attached on-resin or in solution-phase.\"}},{\"@type\":\"Question\",\"name\":\"What is a peptide-drug conjugate?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"A peptide-drug conjugate joins a peptide carrier sequence to a small-molecule payload through a defined linker. The peptide and payload are usually synthesized as separate components before being coupled at a specified stage.\"}},{\"@type\":\"Question\",\"name\":\"Do lipidated peptides count as combined synthesis?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes, lipidated peptides combine a fatty acid or fatty diacid chain with a peptide backbone, usually attached on-resin at a specific lysine side chain. This is one of the most common hybrid synthesis requests in current peptide research.\"}},{\"@type\":\"Question\",\"name\":\"Does a stapled peptide require small-molecule chemistry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes, a stapled peptide uses a small-molecule crosslinker, often installed via ring-closing metathesis, to lock the peptide into a fixed secondary structure. This requires non-natural amino acids at defined positions.\"}},{\"@type\":\"Question\",\"name\":\"Can bulk peptide API be used as the starting material for a conjugation project?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Bulk peptide API can serve as the peptide component for a downstream conjugation step once the attachment chemistry is validated at research scale. Scaling up before validation risks carrying an unoptimized coupling reaction into a larger batch.\"}},{\"@type\":\"Question\",\"name\":\"How is purity verified on a combined peptide-small molecule batch?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Purity is verified at each synthetic stage using HPLC and LC-MS, not only at final release. A conjugation step can introduce new impurities that a single end-point purity check would miss.\"}},{\"@type\":\"Question\",\"name\":\"Is custom synthesis required for hybrid peptide-small molecule projects?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Custom synthesis is the standard route because catalog peptides rarely include the specific linker or small-molecule attachment a hybrid project needs. The project starts from a defined specification covering sequence, attachment point, and linker chemistry.\"}},{\"@type\":\"Question\",\"name\":\"What documentation should accompany a hybrid synthesis lot?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Lot documentation should include analytical data for each intermediate stage, not just a certificate of analysis for the finished conjugate. This lets a researcher trace which stage introduced any deviation from specification.\"}}]}<\/script>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Yes \u2014 small molecule synthesis combines with peptide synthesis for conjugates, lipidated peptides, and stapled constructs. See the staged process for 2026.<\/p>","protected":false},"author":2,"featured_media":2203,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_yoast_wpseo_title":"Can small molecule synthesis be combined with peptide synthesis?","_yoast_wpseo_metadesc":"Yes \u2014 small molecule synthesis combines with peptide synthesis for conjugates, lipidated peptides, and stapled constructs. See the staged process for 2026.","_yoast_wpseo_focuskw":""},"categories":[79],"tags":[],"class_list":["post-2205","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-quality-documentation"],"_links":{"self":[{"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/posts\/2205","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/comments?post=2205"}],"version-history":[{"count":0,"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/posts\/2205\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/media\/2203"}],"wp:attachment":[{"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/media?parent=2205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/categories?post=2205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/simplelifescience.com\/es\/wp-json\/wp\/v2\/tags?post=2205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}